Related Experiment Video

Updated: Apr 25, 2026

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.0K

Pharmacogenomics in the development and characterization of atheroprotective drugs

Efi Valanti1, Alexandros Tsompanidis, Despina Sanoudou

  • 1Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, Athens, 115 27, Greece.

Methods in Molecular Biology (Clifton, N.J.)
|August 25, 2014
PubMed

Insights

Pharmacogenomics advances understanding of drugs for atherosclerosis, a leading cause of cardiovascular disease. This research explores new therapeutic targets and personalized medicine approaches for better treatment outcomes.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Pharmacology
  • Molecular Medicine

Background:

  • Atherosclerosis is a primary cause of cardiovascular disease (CVD), leading to significant morbidity and mortality.
  • Current atheroprotective drugs primarily target low-density lipoprotein (LDL) and high-density lipoprotein (HDL) levels, and inflammation, but cardiovascular risk persists.
  • Adverse drug events and high residual risk necessitate novel therapeutic strategies.

Purpose of the Study:

  • To highlight pharmacogenomics' role in elucidating pharmacological atheroprotection.
  • To review pharmacogenomics investigations of existing and novel atheroprotective drugs.
  • To identify new therapeutic targets at the molecular pathway level.

Main Methods:

  • Review of pharmacogenomics literature related to atherosclerosis.
  • Analysis of molecular pathways involved in drug response.
  • Identification of genetic factors influencing atheroprotective drug efficacy and safety.

Main Results:

  • Pharmacogenomics provides insights into the mechanisms of action of current atheroprotective drugs.
  • Genetic variations influence individual responses to lipid-lowering and anti-inflammatory therapies.
  • Pharmacogenomic studies are identifying novel molecular targets for drug development.

Conclusions:

  • Pharmacogenomics is crucial for understanding and improving pharmacological atheroprotection.
  • Personalized medicine approaches guided by pharmacogenomics can optimize CVD treatment.
  • Further pharmacogenomic research will pave the way for innovative therapeutic strategies against atherosclerosis.

More Related Videos

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

7.7K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
241
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
135